Loading...
Dernières publications
-
Luce Barbat Du Closel, Nathalie Bonello-Palot, Yann Pereon, Andoni Echaniz-Laguna, Jean Philippe Camdessanche, et al.. Clinical and electrophysiological characteristics of women with X-linked Charcot-Marie-Tooth disease. European Journal of Neurology, 2023, 30 (10), pp.3265-3276. ⟨10.1111/ene.15937⟩. ⟨hal-04254200⟩
-
-
Joe-Elie Salem, Marie Bretagne, Baptiste Abbar, Sarah Leonard-Louis, Stéphane Ederhy, et al.. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discovery, 2023, 13 (5), pp.1100-1115. ⟨10.1158/2159-8290.CD-22-1180⟩. ⟨hal-04578810⟩
-
-
Corinna Preuße, Barbara Paesler, Christopher Nelke, Derya Cengiz, Thomas Müntefering, et al.. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathologica, 2022, 144 (2), pp.353-372. ⟨10.1007/s00401-022-02438-z⟩. ⟨hal-03830925⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-03832478⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-04002766⟩
-
-
Stéphane Ederhy, Perrine Devos, Bruno Pinna, Elisa Funck-Brentano, Baptiste Abbar, et al.. 8 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography imaging for the diagnosis of immune checkpoint inhibitors associated myocarditis. Archives of cardiovascular diseases, 2022, ⟨10.1016/j.acvd.2021.12.001⟩. ⟨hal-03561783⟩
-
Chiffres clés
123
Publications avec texte intégral
Open Access
53 %
Mots clés
Adverse drug reactions
Idiopathic inflammatory myopathies
Antibodies
Anticorps anti-agalsidase
Multidisciplinarity
Sphingosine-1-phosphate
COVID-19
Lysosomal storage diseases
Active
Auto-immunité
Immune checkpoint inhibitors
Deep immune profiling
Myositis
Anti‐mitochondrial antibodies
Anti-MDA5 autoantibodies
Anti-drug antibodies
Myocarditis
Middle Aged
Agalsidase
Interferon
Antisynthetase syndrome
Cancer
Auto-antibodies
Biomarker
Anti-synthetase syndrome
Anti-agalsidase antibodies
Inborn errors of metabolism
Aldosterone
Autoimmune diseases
Inflammatory myopathy
B-lymphocyte
Interstitial lung disease
Antisynthetase
Aged
Cytokines
Bioelectrical impedance analysis
Adeno-associated vector
Autoimmunity
Biomarkers
Muscle
AAV antibody
Acid-alpha-glucosidase
Anémie hémolytique
Animals
Gene therapy
Polymyositis
Immunotherapy
Assisted communication devices
Mass cytometry
Adeno-associated virus vector
Anti-Mi2
Adjudication
AAV vector
Pharmacology
Prognosis
Arthritis
AAV humoral immunity
Anticorps spécifique des myosites
Fabry disease
Autoantibodies
Anti-IgE IgG
AAV
Adolescence
Male
Aldostérone
Acute Kidney Injury/epidemiology/etiology
IBM
Adeno-associated virus
Auto‐antibodies
Systems biology
Amyotrophic lateral sclerosis
Machine learning
AAV vectors
Inflammation
IMNM
Anti-interleukin-6
Case reports
Antibody responses
Inclusion body myositis
Abnormal movement
Myopathy
Female
Amyotrophy
Cardio-oncology
Humans
Dependovirus/genetics/immunology
Skeletal muscle
Antisynthétase
Analyses multidimensionnelles
DM
Outcome measures
Biopsy
B cell homeostasis
Autoantibody
Myositis and muscle disease
Data integration
Antiphospholipid syndrome
Dermatomyositis
Adult
Biomarqueurs